Indeed, phase I results of ICOVIR-5, an oAd that is being investigated in several ongoing clinical trials (NCT03714334, NCT03178032, NCT02798406), contains a functional copy of the E1B 55 kDa gene, and its cancer specificity is acquired through deletion in the Rb binding domain of the Ad E1A region and insertion of a tumor-targeting RGD motif at the fiber region of the viral capsid to improve its cancer specificity. The gene discussed is RB1; the disease is cancer.